LATUDA Market Drug Insight and Market Forecast – 2032

LATUDA Market Drug Insight and Market Forecast – 2032

“LATUDA Market Drug Insight and Market Forecast – 2032” report provides comprehensive insights about LATUDA for Bipolar Depression (BD) in the United States, and Japan. A detailed picture of the LATUDA for Bipolar Depression in the United States, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the LATUDA for Bipolar Depression. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LATUDA market forecast analysis for Bipolar Depression in the United States, and Japan descriptive analysis such as SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Bipolar Depression.

Drug Summary

LATUDA (Lurasidone Hydrochloride) is an oral tablet containing lurasidone hydrochloride as an active ingredient. It is approved in the United States for bipolar depression in pediatric patients (10–17 years old) and schizophrenic patients (adolescent and adult) as monotherapy and as adjunctive therapy in adult bipolar depression patients. In the EU, it is only approved for the treatment of schizophrenia, whereas in Japan, it is approved for both schizophrenia and bipolar disorder. Moreover, Lupin Pharma gained approval for a generic version of Sunovion Pharmaceuticals’ LATUDA. However, under the terms of an agreement between generic drug makers and LATUDA's manufacturer, generic versions of the drug will not become available currently.

Lurasidone is a benzothiazole derivative and a second-generation (atypical) antipsychotic. Like other atypical antipsychotics, it antagonizes dopamine D2 receptors and serotonin 5-HT2A and 5-HT7 receptors. It is a partial agonist at 5-HT1A receptors. In addition, it antagonizes adrenergic alpha2A and alpha2C receptors but exhibits minimal affinity for histaminic (H1) and acetyl cholinergic muscarinic (M1) receptors. Modulation of serotonin, norepinephrine, and dopamine is the cornerstone of antidepressant pharmacotherapy. Lurasidone may exert antidepressant effects by increasing dopamine activity in the prefrontal cortex through activity at 5-HT2A and 5-HT1A receptors. It may enhance serotonin activity by downregulating 5-HT2A receptors. In addition, it may increase norepinephrine by antagonizing alpha1 receptors. Antagonism of 5-HT7 receptors may improve mood. The FDA has tentatively approved a generic version of LATUDA in the US.

Mechanism of action

The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated by combining central dopamine D2 and serotonin type 2 (5-HT2A) receptor antagonism.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the LATUDA description, mechanism of action, dosage and administration, research and development activities in Bipolar Depression.

Elaborated details on LATUDA regulatory milestones and other development activities have been provided in this report.

The report also highlights the LATUDA research and development activities in Bipolar Depression across the United States, and Japan.

The report also covers the patents information with expiry timeline around LATUDA.

The report contains forecasted sales of for Bipolar Depression till 2032.

Comprehensive coverage of the late-stage emerging therapies for Bipolar Depression.

The report also features the SWOT analysis with analyst views for LATUDA in Bipolar Depression.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LATUDA Analytical Perspective by DelveInsight

In-depth LATUDA Market Assessment

This report provides a detailed market assessment of LATUDA for Bipolar Depression in the United States, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

LATUDA Clinical Assessment

The report provides the clinical trials information of LATUDA for Bipolar Depression covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Bipolar Depression is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LATUDA dominance.

Other emerging products for Bipolar Depression are expected to give tough market competition to LATUDA and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LATUDA in Bipolar Depression.

Our in-depth analysis of the forecasted sales data of LATUDA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LATUDA in Bipolar Depression.

Key Questions

What is the product type, route of administration and mechanism of action of LATUDA?

What is the clinical trial status of the study related to LATUDA in Bipolar Depression and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LATUDA development?

What are the key designations that have been granted to LATUDA for Bipolar Depression?

What is the forecasted market scenario of LATUDA for Bipolar Depression?

What are the forecasted sales of LATUDA in the United States, and Japan?

What are the other emerging products available and how are these giving competition to LATUDA for Bipolar Depression?

Which are the late-stage emerging therapies under development for the treatment of Bipolar Depression?